Last $17.15 USD
Change Today +0.27 / 1.60%
Volume 16.0K
As of 5:20 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co-spon adr (DSNKY) Snapshot

Open
$17.03
Previous Close
$16.88
Day High
$17.27
Day Low
$17.03
52 Week High
11/19/13 - $20.24
52 Week Low
06/20/13 - $15.77
Market Cap
12.2B
Average Volume 10 Days
30.6K
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
03/26/14
P/E TM
--
Dividend
$0.58
Dividend Yield
1.70%
Current Stock Chart for DAIICHI SANKYO CO-SPON ADR (DSNKY)

Related News

No related news articles were found.

daiichi sankyo co-spon adr (DSNKY) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co-spon adr (DSNKY) Details

Daiichi Sankyo Company, Limited is engaged in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis, etc.; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug. The company’s products also include Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. In addition, it markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma. Further, the company develops, manufactures, and sells non-prescription medications, non-medical goods, cosmetics, and food products; medical devices for healthcare professionals, clinics, and hospitals; drinking water; and pharmaceuticals and drugs for animals, as well as researches, develops, manufactures, and sells vaccines. Additionally, it is involved in the manufacture and contract manufacture of as active pharmaceutical ingredients and intermediates, as well as in the provision of insurance and real estate agency services. The company has a strategic collaboration with Coherus BioSciences, Inc. for the development and commercialization of biosimilar candidates; and a compound library sharing partnership with Astellas Pharma Inc. to provide access to various compound libraries for use in new medicine research and development. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,229 Employees
Last Reported Date: 06/21/13
Founded in 1899

daiichi sankyo co-spon adr (DSNKY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co-spon adr (DSNKY) Key Developments

Daiichi Evaluates Options

Daiichi Sankyo Company, Limited (TSE:4568) is evaluating alternatives. In January 2014, the company started evaluating strategic options for their India operations with The Goldman Sachs Group, Inc. (NYSE:GS) acting as their financial advisor.

Daiichi Sankyo Co., Ltd. and UC San Francisco Announce Collaboration in Drug Discovery Research for Neurodegenerative Diseases

Daiichi Sankyo Co. Ltd. and UC San Francisco established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases. Under the terms of the agreement, Daiichi Sankyo will provide its compound library to the UCSF Institute for Neurodegenerative Diseases (IND), and both parties will perform high-throughput compound screening and optimization together. The project will bring together the drug development capabilities of Daiichi Sankyo with the expertise of world-renowned neuroscientists at UCSF, in a collaborative effort to create multiple drug-discovery programs in debilitating disease areas such as Alzheimer's, Parkinson's, Creutzfeldt-Jakob disease and fronto-temporal dementias -- all conditions for which there currently are no effective therapeutics available. Daiichi Sankyo will provide research funding and payments and royalties for successful clinical progression and commercialization of new products. Daiichi Sankyo will receive the option to enter into an exclusive license agreement to develop and commercialize promising compounds.

Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study

Daiichi Sankyo Company, Limited announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).[1,2] More than 2,200 patients are expected to be enrolled in ENSURE-AF at approximately 250 clinical sites across North America and Europe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSNKY:US $17.15 USD +0.27

DSNKY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.84 USD -0.01
BioMerieux €77.16 EUR +0.33
Exelixis Inc $3.32 USD +0.10
Ipsen SA €29.57 EUR +0.60
Vertex Pharmaceuticals Inc $64.39 USD +1.14
View Industry Companies
 

Industry Analysis

DSNKY

Industry Average

Valuation DSNKY Industry Range
Price/Earnings 14.2x
Price/Sales 1.2x
Price/Book 1.3x
Price/Cash Flow 14.2x
TEV/Sales 0.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO-SPON ADR, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.